期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.792635
关键词
targeted therapy; NSCLC; KRAS; immunotherapy; drug resistance; lung cancer
类别
资金
- AbbVie
- AstraZeneca
- Blueprint Medicines
- Boehringer Ingelheim
- Bristol
- Gilead
- Guardant Health
- Janssen
- Lilly
- MSD
- Novartis
- Pfizer
- Roche
- Rovi
- Sysmex
- Takeda
KRAS is the most frequently altered oncogene in NSCLC, and its mutant tumors have distinct biology and response to treatment, which makes developing effective drugs challenging. The recent discovery of a new pocket in KRAS G12C has led to the development of inhibitors as a new treatment option. However, resistance to targeted KRAS G12C inhibitors is also a concern, and research is ongoing to understand the mechanisms and find suitable drugs. Co-mutations and combination therapy are also areas of interest.
Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is the most frequently altered oncogene in Non-Small Cell Lung Cancer (NSCLC). KRAS mutant tumors constitute a heterogeneous group of diseases, different from other oncogene-derived tumors in terms of biology and response to treatment, which hinders the development of effective drugs against KRAS. Therefore, for decades, despite enormous efforts invested in the development of drugs aimed at inhibiting KRAS or its signaling pathways, KRAS was considered to be undruggable. Recently, the discovery of a new pocket under the effector binding switch II region of KRAS G12C has allowed the development of direct KRAS inhibitors such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, initiating a new exciting era. However, treatment with targeted KRAS G12C inhibitors also leads to resistance, and understanding the possible mechanisms of resistance and which drugs could be useful to overcome it is key. Among others, KRAS G12C (ON) tricomplex inhibitors and different combination therapy strategies are being analyzed in clinical trials. Another area of interest is the potential role of co-mutations in treatment selection, particularly immunotherapy. The best first-line strategy remains to be determined and, due to the heterogeneity of KRAS, is likely to be based on combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据